DK3656384T3 - Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion - Google Patents

Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion Download PDF

Info

Publication number: DK3656384T3
Authority: DK; Denmark
Prior art keywords: pyrimidin; prophylaxis; phenoxy; derivatives; treatment
Prior art date: 2012-10-08

Application number

DK19210167.3T

Other languages

English (en)

Inventor

Kenneth L Arrington

Christopher Burgey

Robert Gilfillan

Yongxin Han

Mehul Patel

Chun Sing Li

Yaozong Li

Yunfu Luo

Jiayi Xu

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-08

Filing date

2013-10-07

Publication date

2022-04-19

2013-10-07 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2022-04-19 Application granted granted Critical

2022-04-19 Publication of DK3656384T3 publication Critical patent/DK3656384T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Enzymes And Modification Thereof (AREA)

DK19210167.3T 2012-10-08 2013-10-07 Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion DK3656384T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN2012001358		2012-10-08
EP17191307.2A EP3295942B1 (en)	2012-10-08	2013-10-07	Combinations comprising 5-phenoxy-3h-pyrimidin-4-one derivatives and their use for the prophylaxis or treatment of infection by hiv

Publications (1)

Publication Number	Publication Date
DK3656384T3 true DK3656384T3 (da)	2022-04-19

Family

ID=49354986

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK19210167.3T DK3656384T3 (da)	2012-10-08	2013-10-07	Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion
DK17191307.2T DK3295942T3 (da)	2012-10-08	2013-10-07	Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion
DK13776702.6T DK2903977T3 (da)	2012-10-08	2013-10-07	5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf som hiv- reverse-transkriptasehæmmere

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK17191307.2T DK3295942T3 (da)	2012-10-08	2013-10-07	Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion
DK13776702.6T DK2903977T3 (da)	2012-10-08	2013-10-07	5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf som hiv- reverse-transkriptasehæmmere

Country Status (46)

Country	Link
US (3)	US9469634B2 (da)
EP (3)	EP2903977B1 (da)
JP (2)	JP5877281B2 (da)
KR (1)	KR101696128B1 (da)
CN (1)	CN104822670B (da)
AP (1)	AP2015008355A0 (da)
AR (1)	AR092876A1 (da)
AU (1)	AU2013329552B8 (da)
BR (1)	BR112015007742B8 (da)
CA (1)	CA2887312C (da)
CL (1)	CL2015000880A1 (da)
CO (1)	CO7350655A2 (da)
CR (1)	CR20150183A (da)
CY (3)	CY1119655T1 (da)
DK (3)	DK3656384T3 (da)
DO (1)	DOP2015000082A (da)
EA (1)	EA033436B1 (da)
EC (1)	ECSP15018618A (da)
ES (3)	ES2645638T3 (da)
GE (1)	GEP20186838B (da)
GT (1)	GT201500088A (da)
HR (3)	HRP20220502T1 (da)
HU (3)	HUE037231T2 (da)
IL (1)	IL238090B (da)
JO (1)	JO3470B1 (da)
LT (3)	LT2903977T (da)
MA (1)	MA37959A2 (da)
MD (1)	MD4625C1 (da)
ME (1)	ME02918B (da)
MX (1)	MX355040B (da)
MY (1)	MY192716A (da)
NI (1)	NI201500048A (da)
NO (1)	NO2903977T3 (da)
NZ (1)	NZ706729A (da)
PE (1)	PE20151787A1 (da)
PH (1)	PH12015500764B1 (da)
PL (3)	PL2903977T3 (da)
PT (3)	PT2903977T (da)
RS (3)	RS59863B1 (da)
SG (1)	SG11201502620UA (da)
SI (3)	SI2903977T1 (da)
TN (1)	TN2015000106A1 (da)
TW (2)	TWI598343B (da)
UA (1)	UA114006C2 (da)
WO (1)	WO2014058747A1 (da)
ZA (1)	ZA201503143B (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103517990A (zh)	2010-10-07	2014-01-15	通用医疗公司	癌症生物标志物
JO3470B1 (ar)	2012-10-08	2020-07-05	Merck Sharp & Dohme	مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
US9228207B2 (en)	2013-09-06	2016-01-05	President And Fellows Of Harvard College	Switchable gRNAs comprising aptamers
US20160221965A1 (en)	2013-09-16	2016-08-04	Bayer Pharma Aktiengesellschaft	Disubstituted trifluoromethyl pyrimidinones and their use
CA2944187C (en) *	2014-04-01	2018-06-19	Merck Sharp & Dohme Corp.	Prodrugs of hiv reverse transcriptase inhibitors
US10301624B2 (en)	2014-06-25	2019-05-28	The General Hospital Corporation	Targeting human satellite II (HSATII)
JP6769963B2 (ja)	2014-08-29	2020-10-14	ティエエッセファルマソチエタレスポンサビリタリミタータ	α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤
FR3027901B1 (fr) *	2014-10-31	2018-03-16	Universite De Reims Champagne Ardenne	Nouveaux procedes appartenant a la famille des pyridazinones.
US10350165B2 (en) *	2014-12-12	2019-07-16	Ojai Energetics Pbc	Methods and systems for forming stable droplets
US12043852B2 (en)	2015-10-23	2024-07-23	President And Fellows Of Harvard College	Evolved Cas9 proteins for gene editing
GB2568182A (en)	2016-08-03	2019-05-08	Harvard College	Adenosine nucleobase editors and uses thereof
WO2018031683A1 (en)	2016-08-09	2018-02-15	President And Fellows Of Harvard College	Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en)	2016-08-24	2023-01-03	President And Fellows Of Harvard College	Incorporation of unnatural amino acids into proteins using base editing
GB2573062A (en)	2016-10-14	2019-10-23	Harvard College	AAV delivery of nucleobase editors
WO2018119359A1 (en)	2016-12-23	2018-06-28	President And Fellows Of Harvard College	Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en)	2017-03-09	2024-02-13	President And Fellows Of Harvard College	Suppression of pain by gene editing
WO2018165631A1 (en)	2017-03-09	2018-09-13	President And Fellows Of Harvard College	Cancer vaccine
CN110914310A (zh)	2017-03-10	2020-03-24	哈佛大学的校长及成员们	胞嘧啶至鸟嘌呤碱基编辑器
US11268082B2 (en)	2017-03-23	2022-03-08	President And Fellows Of Harvard College	Nucleobase editors comprising nucleic acid programmable DNA binding proteins
WO2018209320A1 (en)	2017-05-12	2018-11-15	President And Fellows Of Harvard College	Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP2020534795A (ja)	2017-07-28	2020-12-03	プレジデントアンドフェローズオブハーバードカレッジ	ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
WO2019139645A2 (en)	2017-08-30	2019-07-18	President And Fellows Of Harvard College	High efficiency base editors comprising gam
CA3075727A1 (en)	2017-09-18	2019-03-21	Goldfinch Bio, Inc.	Pyridazinones and methods of use thereof
CA3082251A1 (en)	2017-10-16	2019-04-25	The Broad Institute, Inc.	Uses of adenosine base editors
US12406749B2 (en)	2017-12-15	2025-09-02	The Broad Institute, Inc.	Systems and methods for predicting repair outcomes in genetic engineering
CN112533613A (zh)	2018-02-06	2021-03-19	通用医疗公司	作为肿瘤免疫应答的生物标志物的重复rna
MA52486B1 (fr)	2018-04-30	2023-04-28	Ribon Therapeutics Inc	Pyridazinones utilisés en tant qu'inhibiteurs de parp7
US12157760B2 (en)	2018-05-23	2024-12-03	The Broad Institute, Inc.	Base editors and uses thereof
RS65558B1 (sr)	2018-09-18	2024-06-28	Gfb Abc Llc	Piridazinoni i postupci primene istih
WO2020092453A1 (en)	2018-10-29	2020-05-07	The Broad Institute, Inc.	Nucleobase editors comprising geocas9 and uses thereof
AU2019402998B2 (en) *	2018-12-18	2022-12-15	Merck Sharp & Dohme Llc	Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells
US12351837B2 (en)	2019-01-23	2025-07-08	The Broad Institute, Inc.	Supernegatively charged proteins and uses thereof
AU2020240109A1 (en)	2019-03-19	2021-09-30	President And Fellows Of Harvard College	Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en)	2019-04-17	2020-10-22	The Broad Institute, Inc.	Adenine base editors with reduced off-target effects
WO2020223229A1 (en)	2019-04-29	2020-11-05	Ribon Therapeutics, Inc.	Solid forms of a parp7 inhibitor
KR20220011673A (ko) *	2019-05-22	2022-01-28	머크 샤프 앤드 돔 코포레이션	Hiv 감염된 세포에 대한 선택적 세포독성제로서의 피리디논 유도체
JP2022536364A (ja)	2019-06-13	2022-08-15	ザジェネラルホスピタルコーポレイション	操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法
AU2020357178A1 (en) *	2019-10-04	2022-05-12	Gfb (Abc), Llc	Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
US12435330B2 (en)	2019-10-10	2025-10-07	The Broad Institute, Inc.	Methods and compositions for prime editing RNA
US11691969B2 (en)	2019-10-30	2023-07-04	Ribon Therapeutics, Inc.	Pyridazinones as PARP7 inhibtors
JPWO2021107066A1 (da)	2019-11-28	2021-06-03
TW202146416A (zh)	2019-12-11	2021-12-16	德商拜耳廠股份有限公司	吡唑并三𠯤
BR112022022603A2 (pt)	2020-05-08	2023-01-17	Broad Inst Inc	Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
WO2022020800A2 (en)	2020-07-24	2022-01-27	The General Hospital Corporation	Enhanced virus-like particles and methods of use thereof for delivery to cells
CA3193099A1 (en)	2020-09-24	2022-03-31	David R. Liu	Prime editing guide rnas, compositions thereof, and methods of using the same
CA3203876A1 (en)	2021-01-11	2022-07-14	David R. Liu	Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision
US20240279223A1 (en) *	2021-07-01	2024-08-22	Janssen Pharmaceutica Nv	5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
EP4381057A2 (en)	2021-08-06	2024-06-12	The Broad Institute Inc.	Improved prime editors and methods of use
WO2023076898A1 (en)	2021-10-25	2023-05-04	The Broad Institute, Inc.	Methods and compositions for editing a genome with prime editing and a recombinase
IL313146A (en)	2021-12-03	2024-07-01	Harvard College	Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
WO2023205687A1 (en)	2022-04-20	2023-10-26	The Broad Institute, Inc.	Improved prime editing methods and compositions
WO2023240137A1 (en)	2022-06-08	2023-12-14	The Board Institute, Inc.	Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
WO2024077267A1 (en)	2022-10-07	2024-04-11	The Broad Institute, Inc.	Prime editing methods and compositions for treating triplet repeat disorders
WO2024108092A1 (en)	2022-11-17	2024-05-23	The Broad Institute, Inc.	Prime editor delivery by aav
WO2024168147A2 (en)	2023-02-09	2024-08-15	The Broad Institute, Inc.	Evolved recombinases for editing a genome in combination with prime editing
WO2024206125A1 (en)	2023-03-24	2024-10-03	The Broad Institute, Inc.	Use of prime editing for treating sickle cell disease
WO2025014788A1 (en)	2023-07-07	2025-01-16	Merck Sharp & Dohme Llc	Tetrahydroquinazoline derivatives as selective cytotoxic agents
WO2025081042A1 (en)	2023-10-12	2025-04-17	Renagade Therapeutics Management Inc.	Nickase-retron template-based precision editing system and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5665720A (en)	1992-08-07	1997-09-09	Merck & Co., Inc.	Benzoxazinones as inhibitors of HIV reverse transcriptase
IL139239A0 (en)	1998-04-27	2001-11-25	Centre Nat Rech Scient	3-(amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of hiv related diseases
IT1305313B1 (it)	1998-07-17	2001-05-04	Colla Paolo	3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv)	1999-11-09	1999-11-09	Astra Ab	Compounds
ATE346064T1 (de)	2000-09-15	2006-12-15	Vertex Pharma	Pyrazolverbindungen als protein-kinasehemmer
US20070021449A1 (en)	2003-02-07	2007-01-25	Jan Heeres	Pyrimidine derivatives for the prevention of hiv infection
TW200423930A (en)	2003-02-18	2004-11-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitors
MXPA05010081A (es)	2003-03-24	2005-11-23	Hoffmann La Roche	Bencil-piridazinonas como inhibidores de transcriptasa inversa.
TW200505441A (en)	2003-03-24	2005-02-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitorsⅠ
KR20060124701A (ko)	2004-01-12	2006-12-05	길리애드 사이언시즈, 인코포레이티드	피리미딜 포스포네이트 항바이러스성 화합물 및 그의 사용방법
JP4627315B2 (ja)	2004-03-23	2011-02-09	エフ．ホフマン−ラロシュアーゲー	非ヌクレオシド逆転写酵素阻害剤としてのベンジルピリダジノン誘導体
US7166738B2 (en)	2004-04-23	2007-01-23	Roche Palo Alto Llc	Non-nucleoside reverse transcriptase inhibitors
ES2333802T3 (es)	2004-04-23	2010-03-01	F. Hoffmann-La Roche Ag	Inhibidores no nucleicos de transcriptasa inversa.
US20090264425A1 (en)	2004-12-22	2009-10-22	Pfizer Limited	Chemical compounds
AR057455A1 (es)	2005-07-22	2007-12-05	Merck & Co Inc	Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
CA2625039A1 (en)	2005-10-19	2007-04-26	F. Hoffmann-La Roche Ag	N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors
AU2006303368B2 (en)	2005-10-19	2011-05-26	F. Hoffmann-La Roche Ag	Non-Nucleoside Reverse Transcriptase Inhibitors
US7803940B2 (en)	2006-11-24	2010-09-28	Takeda Pharmaceutical Company Limited	Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
CA2670404A1 (en)	2006-11-24	2008-05-29	Takeda Pharmaceutical Company Limited	Heteromonocyclic compound and use thereof
TW200831085A (en)	2006-12-13	2008-08-01	Merck & Co Inc	Non-nucleoside reverse transcriptase inhibitors
RU2010125220A (ru) *	2007-11-20	2011-12-27	Мерк Шарп Энд Домэ Корп. (Us)	Ненуклеозидные ингибиторы обратной транскриптазы
JP5564435B2 (ja) *	2008-01-08	2014-07-30	メルク・シャープ・アンド・ドーム・コーポレーション	Ｎ−置換ヒドロキシピリミジノンカルボキサミドの製造方法
DK2924034T3 (da)	2010-03-30	2017-02-06	Merck Canada Inc	Farmaceutisk sammensætning, der omfatter en ikke-nukleosid reverse transkriptaseinhibitor
EP2558093A4 (en)	2010-04-08	2013-10-02	Merck Sharp & Dohme	PRODRUGS OF HIV INVERTER TRANSCRIPTASE INHIBITOR
JO3470B1 (ar)	2012-10-08	2020-07-05	Merck Sharp & Dohme	مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CA2944187C (en)	2014-04-01	2018-06-19	Merck Sharp & Dohme Corp.	Prodrugs of hiv reverse transcriptase inhibitors

2013
- 2013-09-29 JO JOP/2013/0284A patent/JO3470B1/ar active
- 2013-10-02 AR ARP130103568A patent/AR092876A1/es active IP Right Grant
- 2013-10-07 MD MD20150047A patent/MD4625C1/ro active IP Right Grant
- 2013-10-07 PT PT137767026T patent/PT2903977T/pt unknown
- 2013-10-07 TW TW105108710A patent/TWI598343B/zh active
- 2013-10-07 CN CN201380061513.7A patent/CN104822670B/zh active Active
- 2013-10-07 HU HUE13776702A patent/HUE037231T2/hu unknown
- 2013-10-07 CA CA2887312A patent/CA2887312C/en active Active
- 2013-10-07 EP EP13776702.6A patent/EP2903977B1/en active Active
- 2013-10-07 DK DK19210167.3T patent/DK3656384T3/da active
- 2013-10-07 SG SG11201502620UA patent/SG11201502620UA/en unknown
- 2013-10-07 LT LTEP13776702.6T patent/LT2903977T/lt unknown
- 2013-10-07 MA MA37959A patent/MA37959A2/fr unknown
- 2013-10-07 AP AP2015008355A patent/AP2015008355A0/xx unknown
- 2013-10-07 WO PCT/US2013/063612 patent/WO2014058747A1/en not_active Ceased
- 2013-10-07 HR HRP20220502TT patent/HRP20220502T1/hr unknown
- 2013-10-07 DK DK17191307.2T patent/DK3295942T3/da active
- 2013-10-07 NZ NZ706729A patent/NZ706729A/en unknown
- 2013-10-07 PL PL13776702T patent/PL2903977T3/pl unknown
- 2013-10-07 ES ES13776702.6T patent/ES2645638T3/es active Active
- 2013-10-07 MX MX2015004448A patent/MX355040B/es active IP Right Grant
- 2013-10-07 EP EP17191307.2A patent/EP3295942B1/en active Active
- 2013-10-07 SI SI201330835T patent/SI2903977T1/sl unknown
- 2013-10-07 RS RS20200052A patent/RS59863B1/sr unknown
- 2013-10-07 LT LTEP19210167.3T patent/LT3656384T/lt unknown
- 2013-10-07 LT LTEP17191307.2T patent/LT3295942T/lt unknown
- 2013-10-07 PT PT171913072T patent/PT3295942T/pt unknown
- 2013-10-07 SI SI201331974T patent/SI3656384T1/sl unknown
- 2013-10-07 EA EA201590674A patent/EA033436B1/ru not_active IP Right Cessation
- 2013-10-07 KR KR1020157011661A patent/KR101696128B1/ko active Active
- 2013-10-07 GE GEAP201313818A patent/GEP20186838B/en unknown
- 2013-10-07 EP EP19210167.3A patent/EP3656384B1/en active Active
- 2013-10-07 RS RS20220359A patent/RS63112B1/sr unknown
- 2013-10-07 ES ES19210167T patent/ES2909190T3/es active Active
- 2013-10-07 HU HUE19210167A patent/HUE058903T2/hu unknown
- 2013-10-07 TW TW102136225A patent/TWI538907B/zh active
- 2013-10-07 PL PL17191307T patent/PL3295942T3/pl unknown
- 2013-10-07 NO NO13776702A patent/NO2903977T3/no unknown
- 2013-10-07 UA UAA201504486A patent/UA114006C2/uk unknown
- 2013-10-07 AU AU2013329552A patent/AU2013329552B8/en active Active
- 2013-10-07 DK DK13776702.6T patent/DK2903977T3/da active
- 2013-10-07 JP JP2015535852A patent/JP5877281B2/ja active Active
- 2013-10-07 ME MEP-2017-264A patent/ME02918B/me unknown
- 2013-10-07 SI SI201331662T patent/SI3295942T1/sl unknown
- 2013-10-07 HR HRP20171819TT patent/HRP20171819T1/hr unknown
- 2013-10-07 PE PE2015001782A patent/PE20151787A1/es active IP Right Grant
- 2013-10-07 PT PT192101673T patent/PT3656384T/pt unknown
- 2013-10-07 MY MYPI2015000836A patent/MY192716A/en unknown
- 2013-10-07 RS RS20171164A patent/RS56543B1/sr unknown
- 2013-10-07 ES ES17191307T patent/ES2770774T3/es active Active
- 2013-10-07 PL PL19210167T patent/PL3656384T3/pl unknown
- 2013-10-07 BR BR112015007742A patent/BR112015007742B8/pt active IP Right Grant
- 2013-10-07 US US14/047,515 patent/US9469634B2/en active Active
- 2013-10-07 HU HUE17191307A patent/HUE048670T2/hu unknown
2015
- 2015-03-23 TN TNP2015000106A patent/TN2015000106A1/fr unknown
- 2015-04-01 IL IL238090A patent/IL238090B/en active IP Right Grant
- 2015-04-06 PH PH12015500764A patent/PH12015500764B1/en unknown
- 2015-04-07 NI NI201500048A patent/NI201500048A/es unknown
- 2015-04-08 CR CR20150183A patent/CR20150183A/es unknown
- 2015-04-08 CO CO15077967A patent/CO7350655A2/es unknown
- 2015-04-08 DO DO2015000082A patent/DOP2015000082A/es unknown
- 2015-04-08 GT GT201500088A patent/GT201500088A/es unknown
- 2015-04-08 CL CL2015000880A patent/CL2015000880A1/es unknown
- 2015-05-07 ZA ZA2015/03143A patent/ZA201503143B/en unknown
- 2015-05-12 EC ECIEPI201518618A patent/ECSP15018618A/es unknown
2016
- 2016-01-25 JP JP2016011415A patent/JP6097422B2/ja active Active
- 2016-02-01 US US15/012,445 patent/US9718819B2/en active Active
2017
- 2017-06-07 US US15/616,756 patent/US10189831B2/en active Active
- 2017-11-20 CY CY20171101214T patent/CY1119655T1/el unknown
2020
- 2020-01-30 HR HRP20200158TT patent/HRP20200158T1/hr unknown
- 2020-02-04 CY CY20201100097T patent/CY1122585T1/el unknown
2022
- 2022-03-30 CY CY20221100247T patent/CY1125202T1/el unknown

Also Published As

Publication number	Publication date
EP3295942B1 (en)	2019-11-20
TN2015000106A1 (en)	2016-06-29
ES2909190T3 (es)	2022-05-05
PL3656384T3 (pl)	2022-04-04
ZA201503143B (en)	2016-06-29
CY1119655T1 (el)	2018-04-04
NO2903977T3 (da)	2018-02-17
US10189831B2 (en)	2019-01-29
PT3295942T (pt)	2020-02-18
MD4625B1 (ro)	2019-04-30
HRP20220502T1 (hr)	2022-05-27
TW201420576A (zh)	2014-06-01
AU2013329552A1 (en)	2015-04-16
CL2015000880A1 (es)	2015-08-28
GEP20186838B (en)	2018-04-10
AU2013329552C1 (en)	2016-12-22
JP5877281B2 (ja)	2016-03-02
BR112015007742B8 (pt)	2021-03-23
HRP20200158T1 (hr)	2020-08-07
EP3656384B1 (en)	2022-02-23
HK1252786A1 (en)	2019-05-31
AU2013329552B8 (en)	2017-01-12
HUE048670T2 (hu)	2020-08-28
RS63112B1 (sr)	2022-05-31
BR112015007742A2 (pt)	2017-08-08
LT2903977T (lt)	2017-12-11
US20160145255A1 (en)	2016-05-26
TW201623256A (zh)	2016-07-01
MD4625C1 (ro)	2019-11-30
DOP2015000082A (es)	2015-08-16
WO2014058747A1 (en)	2014-04-17
JP2016128470A (ja)	2016-07-14
IL238090B (en)	2019-02-28
UA114006C2 (xx)	2017-04-10
SG11201502620UA (en)	2015-05-28
PL2903977T3 (pl)	2018-01-31
US9718819B2 (en)	2017-08-01
AR092876A1 (es)	2015-05-06
MA37959A2 (fr)	2017-12-29
ECSP15018618A (es)	2019-06-30
JP2015533123A (ja)	2015-11-19
DK2903977T3 (da)	2017-12-04
CN104822670A (zh)	2015-08-05
CA2887312A1 (en)	2014-04-17
ME02918B (me)	2018-10-20
CY1125202T1 (el)	2024-02-16
JO3470B1 (ar)	2020-07-05
CO7350655A2 (es)	2015-08-10
MX2015004448A (es)	2016-02-17
MX355040B (es)	2018-03-28
DK3295942T3 (da)	2020-02-10
SI3656384T1 (sl)	2022-05-31
KR101696128B1 (ko)	2017-01-13
US20170349585A1 (en)	2017-12-07
CR20150183A (es)	2015-08-10
LT3656384T (lt)	2022-05-10
BR112015007742B1 (pt)	2021-01-19
PE20151787A1 (es)	2015-12-03
ES2645638T3 (es)	2017-12-07
PH12015500764A1 (en)	2015-07-27
LT3295942T (lt)	2020-02-10
EP2903977A1 (en)	2015-08-12
AU2013329552B2 (en)	2016-09-15
EP3656384A1 (en)	2020-05-27
GT201500088A (es)	2017-09-28
HRP20171819T1 (hr)	2017-12-29
PT3656384T (pt)	2022-03-22
CY1122585T1 (el)	2021-01-27
SI3295942T1 (sl)	2020-03-31
ES2770774T3 (es)	2020-07-03
MY192716A (en)	2022-09-05
EP3295942A1 (en)	2018-03-21
KR20150065186A (ko)	2015-06-12
HK1207369A1 (en)	2016-01-29
TWI538907B (zh)	2016-06-21
EP2903977B1 (en)	2017-09-20
HUE037231T2 (hu)	2018-08-28
CA2887312C (en)	2017-02-28
AP2015008355A0 (en)	2015-04-30
JP6097422B2 (ja)	2017-03-15
NI201500048A (es)	2016-06-29
RS59863B1 (sr)	2020-03-31
CN104822670B (zh)	2018-01-12
MD20150047A2 (ro)	2015-08-31
PH12015500764B1 (en)	2019-04-05
SI2903977T1 (sl)	2017-12-29
HUE058903T2 (hu)	2022-09-28
TWI598343B (zh)	2017-09-11
RS56543B1 (sr)	2018-02-28
US9469634B2 (en)	2016-10-18
PL3295942T3 (pl)	2020-05-18
NZ706729A (en)	2018-09-28
PT2903977T (pt)	2017-11-14
US20140100231A1 (en)	2014-04-10
EA033436B1 (ru)	2019-10-31
EA201590674A1 (ru)	2016-02-29

Publication	Publication Date	Title
DK3656384T3 (da)	2022-04-19	Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion
DK3043865T3 (da)	2021-02-01	Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
DK2903967T6 (da)	2020-07-13	Acylaminopyrimidinderivater til behandling af virusinfektioner og andre sygdomme
DK3317286T3 (da)	2019-12-02	Cykliserede sulfamoylarylamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b
CL2016000424A1 (es)	2017-07-14	Métodos y composiciones para el arn-guiado tratamiento de la infección por vih
DK2958900T3 (da)	2019-07-01	2-aminopyrimidinderivater til behandling af virusinfektioner
DK3494972T3 (da)	2024-01-29	Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion
DK3121164T3 (da)	2020-05-11	Sulfamoylpyrrolamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b
ZA201500921B (en)	2021-10-27	Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
DK3366307T3 (da)	2021-11-01	Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK2903600T3 (da)	2022-09-26	Virusholdig formulering og anvendelse deraf
DK2958588T3 (da)	2017-11-20	Kombination af vaccination og hæmning af PD-1-reaktionsvejen
DK2818481T3 (da)	2019-10-14	Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK2838900T3 (da)	2019-10-14	Forbindelser og fremgangsmåder til antiviral behandling
DK2882496T3 (da)	2019-11-11	Behandling og diagnosticering af melanom
IL245213A0 (en)	2016-06-30	Inhibitors of human immunodeficiency virus replication
DK2688557T3 (da)	2017-11-27	Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
DK3238707T3 (da)	2021-03-22	Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet
DK2882441T3 (da)	2020-05-25	Behandling af immunrelaterede og inflammatoriske sygdomme
DK3838271T3 (da)	2025-09-29	Behandling af forhøjede niveauer af eosinophiler og/eller basophiler
DK3292873T3 (da)	2019-06-03	Kombination af vaccination og hæmning af PD-1-vejen
DK2854910T3 (da)	2020-05-04	Ceramidniveauer i behandling og forebyggelse af infektioner
DK2939665T3 (da)	2019-06-11	Farmaceutisk sammensætning til behandling af hiv-infektioner
DK3004340T3 (da)	2020-09-21	Behandling af glutenintolerance og beslægtede tilstande
DK2892556T3 (da)	2019-08-05	Sammensætninger og fremgangsmåder til behandling af sygdomme